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Brain iron is tightly regulated by a multitude of proteins to ensure homeostasis. Iron
dyshomeostasis has become a molecular signature associated with aging which is
accompanied by progressive decline in cognitive processes. A common theme in
neurodegenerative diseases where age is the major risk factor, iron dyshomeostasis
coincides with neuroinflammation, abnormal protein aggregation, neurodegeneration,
and neurobehavioral deficits. There is a great need to determine the mechanisms
governing perturbations in iron metabolism, in particular to distinguish between
physiological and pathological aging to generate fruitful therapeutic targets for
neurodegenerative diseases. The aim of the present review is to focus on the age-related
alterations in brain iron metabolism from a cellular and molecular biology perspective,
alongside genetics, and neuroimaging aspects in man and rodent models, with respect
to normal aging and neurodegeneration. In particular, the relationship between iron
dyshomeostasis and neuroinflammation will be evaluated, as well as the effects of
systemic iron overload on the brain. Based on the evidence discussed here, we suggest
a synergistic use of iron-chelators and anti-inflammatories as putative anti-brain aging
therapies to counteract pathological aging in neurodegenerative diseases.
Keywords: brain iron, iron regulation, iron overload, aging, neuroinflammation, neurodegenerative diseases,
Alzheimer’s disease, Parkinson’s disease
INTRODUCTION
Iron dyshomeostasis is a molecular signature associated with aging, accompanied by progressive
decline in cognitive processes. The transition element, iron, is the most abundant metal in the
brain and performs pleiotropic functions including neurotransmitter synthesis, myelination of
neurons and adenosine triphosphate (ATP) synthesis (Ward et al., 2014). Iron undergoes dynamic
redox coupling through reversible oxidation/reduction of ferrous iron (Fe2+) and ferric iron
(Fe3+). Hydrogen peroxide is often generated in the cell, especially as it is a by-product of normal
mitochondrial respiration and can react with Fe2+ to produce hydroxyl free radicals in the Fenton
reaction and increase reactive oxygen species (ROS), enhancing oxidative stress and eventually
lead to cell damage (Kruszewski, 2003). However, whilst readily demonstrated in experimental
systems, the Fenton reaction has been hard to observe in vivo, particularly due to the difficulties in
measuring free radical reactions in vivo. Nonetheless, knowledge of free radical chemistry in vitro
combined with accumulating circumstantial evidence e.g., use of iron chelators (see below), suggest
a role for Fenton chemistry in free radical-mediated pathology. Consequently, the homeostatic
neuroregulation of iron is tightly controlled for this reason, this “goldilocks” mineral can lead to
perturbations in neuronal function if deficient or in excess. The aim of the present review is to focus
on the age-related alterations in ironmetabolism from a cellular andmolecular biology perspective,
alongside genetics, and neuroimaging aspects, in man and rodent models. Herein, therapeutic
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interventions are proposed to maintain healthy brain aging and
attenuate neurodegenerative disease.
SYSTEMIC IRON HOMEOSTASIS
Iron is acquired from the diet in the form of heme and iron
salts and initially absorbed by the gut (Figure 1) which functions
as a key modulator of iron concentration in the body (Ganz,
2013; Duck and Connor, 2016). Divalent metal transporter-
1 (DMT1) and ferroportin-1 (Fpn) transport iron across the
duodenal mucosa into the bloodstream (Fuqua et al., 2012). Fpn-
mediated eﬄux is facilitated by a membrane-bound ferroxidase,
hephaestin, which oxidizes Fe2+ to Fe3+ (Steere et al., 2012). In
the serum, two Fe3+ are bound by apo-transferrin (apo-Tf) to
become holotransferrin (holo-Tf), and transported in the latter
form throughout the body. Approximately 30% of circulating
iron is holo-Tf (Aisen et al., 2001), while the remaining iron
associates with citrate, ATP and ascorbate to form low molecular
weight complexes in the blood (Qian and Shen, 2001; Ma et al.,
2009). Hepcidin is a peptide hormone produced by hepatocytes
when exposed to excess iron, inducing cellular degradation
of Fpn, thereby attenuating duodenal iron uptake (Ganz and
Nemeth, 2012). Cells often express the Transferrin Receptor-1
(TfR1) on the plasma membrane which on binding to holo-Tf
forms a complex (Lambe et al., 2009) and is endocytosed into
an endosome. Within the endosome Fe3+ is reduced to Fe2+
by six transmembrane epithelial antigen of protein 3 (STEAP3,
a metalloreductase) and Fe2+ dissociates from transferrin (Tf).
The Fe2+ is then exported to the cytoplasm via DMT1 while
Tf is recycled. Cytosolic Fe2+ can be used for metabolism,
e.g., for synthesis of mitochondria iron-sulfur proteins, or
sequestered/stored by ferritin to prevent iron engaging in redox
reactions leading to toxicity (Rouault, 2006; Duck and Connor,
2016).
IRON ENTRY INTO THE BRAIN
The systemic circulation is physically separated from the
brain parenchyma by two cellular barriers: the blood brain
barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB)
(McCarthy and Kosman, 2015), and iron is transported across the
barriers by an orchestra of molecular players. The BBB comprises
brain microvascular endothelial cells (BVEC), astrocytes and
pericytes which form stringent tight-junctions (Rouault and
Cooperman, 2006), limiting access into the brain (Figure 2).
The mechanism of iron entry into the brain comprises of two
transmembrane steps: iron uptake into BVEC at the luminal
(blood) side and iron eﬄux into the brain interstitial fluid at the
abluminal (brain) side (Mills et al., 2010). Holo-Tf in the systemic
circulation binds to luminal receptors (of BVEC) and the Holo-
Tf/TfR1 complex internalized into endosomes (Hentze et al.,
2004).Within the endosome, Fe3+ is reduced by a ferri-reductase,
possibly duodenal cytochrome b (Dcytb) or Steap2, and liberated
from Tf (De Domenico et al., 2008). The resulting Fe2+ ions
are then exported from the endosome into the cytosol, likely
via DMT1, although DMT1 expression and function in BVEC
remains contentious. Cellular Fe2+ is released into the interstitial
fluid through Fpn on the BVEC abluminal side, requiring re-
oxidization of Fe2+ by ferroxidases such as hephaestin and/or
extracellular ceruloplasmin (Ward et al., 2014; McCarthy and
Kosman, 2015).
Iron entry into the brain may also occur through epithelial
cells of the choroid plexus which constitute the BCSFB (Rouault
et al., 2009). In contrast to the capillaries of the BBB, the choroid
plexus consists of fenestrated capillaries that are readily crossed
by holo-Tf to reach the choroidal epithelium (Brown et al., 2004)
and iron crosses the choroidal epithelium to enter the ventricles.
In situ hybridization revealed significant expression of TfR1,
DMT1, Fpn, and ferroxidases (ceruloplasmin/hephaestin) in the
choroid plexus (Dickson et al., 1985; Giometto et al., 1990; Wu
et al., 2004; Rouault et al., 2009). This suggests that DMT1 is
needed to release iron from the holo-Tf/TfR1 complex and iron
is exported from the choroid epithelium to the CSF by Fpn, aided
by the ferroxidases. Interestingly, the choroid plexus produces
CSF that fills all four ventricles and bathes the interstitium of
the central nervous system (CNS) (Rouault and Cooperman,
2006). It is important to emphazise that there is no diffusional
barrier separating the ventricular CSF from the brain interstitial
fluid. Once iron enters the interstitial fluid or ventricular CSF,
it binds to Apo-Tf synthesized locally by the choroid plexus and
oligodendrocytes to form holo-Tf (Leitner and Connor, 2012)
and supplies CNS cells expressing TfR1. There is sparse data on
Tf transport from the brain to the blood but apo- and holo-Tf
may pass through the arachnoid villi and cribriform plate into the
veins to enter the systemic circulation (Johansson et al., 2008).
Diurnal variation of iron content in the ventral midbrain has
been reported (Unger et al., 2009), reinforcing the notion that
mechanisms exist for iron export from the brain to the systemic
compartment. The recent discovery of the glymphatic system
(Iliff et al., 2012; Papadopoulos and Verkman, 2013; Louveau
et al., 2015; Trevaskis et al., 2015), a “lymphatic” system in the
brain, may be one of the routes by which transition metals
including iron are transported and cleared from the brain—
through convective bulk flow of interstitial fluid, possibly aided
by astrocytic aquaporin 4 channels (Figure 3). The mechanisms
underlying the glymphatic system remain to be established.
BRAIN IRON HOMEOSTASIS
The brain comprises neurons and the glia, oligodendrocytes,
astrocytes, andmicroglial, each with their specific complement of
molecules in regulating their cellular iron content. Neurons can
uptake both Tf-bound and non Tf-bound iron (via DMT1) from
the interstitial fluid (Burdo et al., 2001). Iron is essential for axon
myelination and oligodendrocytes only acquire non Tf-bound
iron via the T-cell immunoglobulin and mucin domain (Tim-
2), a ferritin receptor exclusively expressed in oligodendrocytes
(Han et al., 2011), since TfR1 is not expressed by mature
oligodendrocytes (Moos et al., 2007). Astrocytes on the other
hand, express TfR1 but non Tf-bound iron is considered the
main iron source for astrocytes in vivo (Moos and Morgan, 2004;
Bishop et al., 2010) as TfR1 expression has only been reported
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FIGURE 1 | Systemic iron regulation. Iron-loaded apo-transferrin (Apo-Tf) forms holo-Tf and binds to Tf receptor-1 (TfR1) on the intestinal membrane and the
holo-Tf/TfR1complex is endocytosed via clathrin-coated pits (Lambe et al., 2009; Duck and Connor, 2016). STEAP3 reduces the ferric iron (Fe3+) to ferrous iron
(Fe2+) in the endosome and Fe2+ is transported into cytosol by divalent metal transporter-1 (DMT1), contributing to the labile iron pool. The apo-Tf/TfR1 complex is
recycled to the cell membrane, where apo-Tf is released to bind to circulating plasma Fe3+. The excess iron is either sequestrated by ferritin or exported out of the cell
by ferroportin (Fpn), in association with hephaestin (Heph). Hepcidin binds to Fpn mediating Fpn internalization and degradation, thereby preventing dietary iron
absorption, dependent on the body iron status (Ganz, 2013).
in hippocampal astrocytic cultures (Pelizzoni et al., 2013).
Astrocytic plasmamembranesmay express a ferri-reductase close
to DMT1, to reduce Fe3+ to Fe2+, facilitating iron uptake (Bishop
et al., 2010). Microglia phagocytose cells to recycle iron, with
excess iron being stored with ferritin. Ferritin is the principal
storage protein used to sequester iron in neurons and glia, and
indeed in many cell types. The primary eﬄux iron transporter
is Fpn, working in concert with ceruloplasmin to generate Fe3+
iron for cell export (Ward et al., 2014). Depending on iron
status (iron overload or deficiency), hepcidin can accordingly
regulate the expression of Fpn to increase or decrease the eﬄux
of intracellular iron (Figure 4). Cellular iron levels are also
modulated at the post-transcriptional (or translational) level by
binding to the iron responsive elements (IREs) of mRNA of iron
regulatory proteins (IRPs), e.g., ferritin, TfR1 (Ward et al., 2014).
In the presence of surplus iron, IRPs remain inactive and do not
bind to the IREs on the mRNAs of ferritin and TfR1, enhancing
ferritin synthesis while TfR1 mRNA undergoes degradation by
nucleases (Wallander et al., 2006; Anderson et al., 2012). On the
other hand, in conditions of iron deficiency, the IRPs bind to
the IREs on the mRNAs in the 3′-untranslated region (UTR)
to prevent TfR1 mRNA degradation resulting in TfR1 synthesis.
The binding of IRPs to the IREs in the 5′-UTR of ferritin mRNA
prevents translation of ferritin and ferritin is not synthezised.
The cellular and molecular mechanisms operant in regulation
of iron uptake, transport, and metabolism in the brain are
intricate and intertwined. Disruption of these mechanisms
leads to iron dyshomeostasis, which has become a common
feature in neurodegenerative diseases (Ward et al., 2014). A
plethora of iron homeostatic mechanisms appear to be affected
during physiological aging and may explain the increased
susceptibility of the aged brain to disease and why aging is
the major risk factor in neurodegenerative diseases. However,
octogenarians/centurions, or “super-agers” are known, who
remain disease—and disability-free throughout aging. Thus, it
is imperative to distinguish between normal and pathological
aging to develop fruitful therapeutic targets. The mechanisms
underlying iron perturbations in the brain are discussed
with respect to normal aging and in neurodegeneration,
including the relationship between iron dyshomeostasis, and
neuroinflammation, and the effects of systemic iron overload on
the brain.
AGE-ASSOCIATED IRON DEPOSITION
Humans
Based on human post-mortem analyses, total iron deposition
is positively correlated with age with maximal levels achieved
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FIGURE 2 | Schematic of the transportation of iron across the blood brain barrier (BBB) and into the brain. Apo-transferrin (Apo-Tf) binds to ferric iron (Fe3+) in the
systemic circulation to form holo-Tf (Ke et al., 2005; Moos et al., 2007; Leitner and Connor, 2012). The BBB, formed by tight junctions between brain vascular
endothelial cells (BVECs), limits transport of materials from the blood into the brain. Systemic holo-Tf binds to the Tf receptor-1 (TfR1) located on the luminal (blood)
side (BVECs), and the newly formed holo-Tf/TfR1 complex is internalized into BVECs. Endosomal ferri-reductase catalyzes the reduction of Fe3+ to ferrous iron
(Fe2+), enabling Fe2+ export into the cytosol from the endosome possibly through divalent metal transporter-1 (DMT1). At the abluminal (brain) side, the cellular Fe2+
enters the interstitium through an iron exporter, ferroportin, aided by rapid oxidation of Fe2+ to Fe3+ by ferroxidases (ceruloplasmin, hephaestin). The expression of
polarized DMT1 in astrocytic foot-processes from close associations with BVECs, may facilitate rapid uptake of Fe2+ following their release into the perivascular space
of the brain (Ward et al., 2014). Neurons can influx iron via a holo-Tf/TfR1-dependent uptake mechanism. In contrast, detectable levels of TfR1 are not expressed by
either astrocytes nor oligodendrocytes. Tim-2, a ferritin receptor (Han et al., 2011), aids in oligodendrocyte iron uptake while non-Tf bound iron is taken up via DMT1.
in the basal ganglia including the putamen, globus pallidus,
and substantia nigra (Hallgren and Sourander, 1958; Connor
et al., 1990, 1992, 1995). Meanwhile, the lowest concentrations
were observed in the cerebral cortex, brainstem, and cerebellum
(Zecca et al., 2004; Ramos et al., 2014).
At the cellular level, oligodendrocytes are the predominant
glial cells enriched with iron, ferritin, and Tf in both gray and
white matter. The concentration of iron and associated proteins
remains constant in the oligodendroglia with age (Connor
et al., 1990). Iron and ferritin immuno-reactive microglial and
astroglial cells generally showed increased expression during
aging in the cerebral cortex, cerebellum, hippocampus, amygdala,
and basal ganglia. In contrast to the gray matter, where
iron is confined to ferritin-positive protoplasmic astrocytes, Tf
expression in fibrous astroglia was noted exclusively in the white
matter, particularly in aged individuals. The paucity of staining
of iron and related proteins in neurons implies a primary role
for glial cells, particularly astrocytes and microglia, in altering
iron metabolism during the process of ageing (Connor et al.,
1990).
The distribution of TfR1 exhibits disparity with ferritin and
iron distribution in the human brain. Autoradiography of TfR1
revealed increased density in the neocortex, with moderate
intensities in the putamen and caudate nucleus. The lowest
density of TfR1 was evident in the globus pallidus, substantia
nigra, and white matter regions (Griffiths and Crossman, 1996).
Conversely, immunohistochemical staining of TfR1 did not
reveal a consistent staining pattern (Connor and Menzies,
1996). In the dentate gyrus of the hippocampus, many but
not all neurons, were immuno-positive for TfR1. In the
striatum, TfR1-immunoreactivity was evident in both neurons
and astrocytes. The iron-rich deep cerebellar nuclei did not
stain for TfR1 but oligodendrocytes prevalent in peri-neuronal
positions did exhibit immuno-positivity. Furthermore, the white
matter tracts revealed light staining and was distributed between
oligodendrocytes and fibrous astrocytes. The difference in TfR1
and ferritin is unsurprising, considering iron induces ferritin
expression but decreases TfR1 expression.
More detailed analysis on age-related iron deposition has
been undertaken in neuromelanin pigmented neurons of
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FIGURE 3 | Neuro-vascular unit and the glymphatic pathway. The neuro-vascular unit (A) regulates transport into the brain and the glymphatic pathway enables
communication between the microvasculature and neurons, with astrocytes acting as intermediators (B). The CSF enters the brain parenchyma along paravascular
spaces surrounding the penetrating arteries (Virchow-Robin space) exchanges with the brain interstitial fluid (Iliff et al., 2012, 2013) that bathes the brain (red arrow B;
para-arterial CSF influx route). Interstitial solutes are subsequently cleared to paravascular spaces located in the vicinity of large caliber draining veins (purple arrow;
para-venous interstitial fluid clearance route). The trans-parenchymal pathway (green arrow) allows convective bulk flow between the paravascular CSF influx and
interstitial fluid efflux pathways facilitated by the exclusive perivascular astrocytic end-feet expressed aquaporin-4 (Aqp4) water channels (Nielsen et al., 1997;
Mathiisen et al., 2010). This convective bulk flow mediates clearance of the interstitial solutes from the brain.
substantia nigra and locus coeruleus. The substantia nigra
exhibits a linear increase in total iron concentration and
ferritin with aging, remaining constant in the locus coerulus,
underscoring the importance of the former in neurodegenerative
diseases (Zecca et al., 1996, 2001). Interestingly, Perl’s staining
demonstrated deposits of iron in glial cell population and
neuromelanin-deficient neurons in the substantia nigra of
healthy individuals (Zecca et al., 2004). On the contrary,
reactive iron deposits were not observed in neurons expressing
neuromelanin, indicative of effective iron-sequestration by
neuromelanin (Zecca et al., 2004, 2008a). The concentration
of iron-neuromelanin complexes also increases with age in
neurons of the putamen, premotor cortex and cerebellum,
demonstrating augmented ironmobilization during aging (Zecca
et al., 2008a). It is important to note that binding of iron to
neuromelanin is variable in neurons of different brain regions
(Ward et al., 2014). Evaluating the mechanism further, excess
iron is released from neuromelanin and augments oxidative
stress in mitochondria, leading to mitochondrial impairment.
Both superoxide dismutase and deferoxamine counteracted
the increase in iron levels, confirming the involvement of
iron in superoxide production (Shamoto-Nagai et al., 2006).
This transition of a shift in function of neuromelanin from
being protective to detrimental, may explain the selective
vulnerability of aged dopamine neurons to PD (Ayton and Lei,
2014). Moreover, co-localization of iron and dopamine in the
substantia nigra renders the region susceptible to oxidative stress
(Hare et al., 2014). Mice harboring 6-hydroxydopamine lesions
demonstrated iron and dopamine dyshomeostasis, leading to
increased iron and dopamine product mediated oxidative stress,
which contributes to neurodegeneration in PD.
Rodents
In congruence with human studies, in rodents, the
oligodendrocyte is also the principal cell involved in iron
regulation (Todorich et al., 2009). Oligodendrocytes undergo a
complex and finely tuned program of proliferation, migration,
differentiation, and myelination to produce insulating sheath
of axons (Bradl and Lassmann, 2010). Since iron is required
as a co-factor for myelin synthesis, this contributes to why
oligodendrocytes is the CNS cell with the highest intracellular
iron content. As in humans, an increase in ferritin–and
iron-staining in microglia was observed with aging in the rat
hippocampus, basal ganglia, and cerebellum (Roskams and
Connor, 1994; Focht et al., 1997). In contrast to humans, rat
astrocytes are the only neuroglial cell that does not stain for
iron or iron-regulatory proteins. Interestingly, myelin-deficient
rats lacking a mature population of oligodendrocytes, exhibit
altered cellular iron distribution with increased iron in astrocytes
and microglia while Tf remained unchanged (Connor and
Menzies, 1990; Todorich et al., 2009). Apparently in rodents,
astrocytes may accumulate iron when oligodendrocytes are
compromised. There are striking differences between human
and rodent astrocytes that may help explain these discrepant
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FIGURE 4 | Overview of cellular metabolism of iron in the brain. Transferrin (Tf) laden with iron (holo-Tf) binds to the Tf receptor-1 (TfR1), and iron enters the cell by
receptor-mediated endocytosis and into endosomes (Moos and Morgan, 2004; Moos et al., 2007). Iron can be released from endosomes into the cytosolic labile iron
pool, from here, iron can either be utilized in cellular processes or stored in ferritin (Ward et al., 2014). Additionally, ferrous iron (Fe2+) may enter cells via divalent metal
transporter-1 (DMT1) into the cytosolic labile iron pool, but only a relatively small amount of ferrous iron is transported by this way. Excess Fe2+ may also be exported
from the cell by ferroportin (Fpn), aided by membrane-bound ferroxidase ceruloplasmin (only present in astrocytes) (De Domenico et al., 2007). Ceruloplasmin is not
known to regulate the Fpn-mediated export but stabilizes Fpn. Ferroxidases (hephaestin and ceruloplasmin) in the circulation or the cell surface oxidize Fe2+ to ferric
(Fe3+) iron and facilitates binding to apo-Tf to form holo-Tf for vasculature transport. Hepcidin in the extracellular space inhibits iron export by binding to Fpn and
mediates Fpn internalization and degradation (Ganz and Nemeth, 2012). The extracellular iron status modulates the cellular hepcidin levels by interactions between
TfR1 and HFE TfR1which in turn regulates cellular hepcidin levels via unknown mechanisms. The key proteins involved in peripheral and central iron homeostasis are
similar. However, the brain has its own unique regulatory mechanisms, as it is isolated by the cellular barriers–the blood brain and blood-CSF barriers. The exact way
in which the different brain cell types interact with one another to maintain iron homeostasis remains to be elucidated. Also, the mechanism underlying the cross-talk
between the brain and the periphery to regulate global iron homeostasis is not fully characterized.
findings (Oberheim et al., 2009). Briefly, distinct morphologic
classes of GFAP-positive astroglial cells (namely interlaminar
and varicose projection astrocytes) have been exclusively
identified in adult human temporal cortex (Oberheim et al.,
2009). Long processes of interlaminar astrocytes, characterized
by their tortuous appearance span cortical layers I-IV, terminate
in the neuropil or occasionally on the vasculature. In layers
V-VI, polarized astrocytes with long processes characterized
by varicosities penetrating delimited domains of neighboring
astrocytes in a random fashion have been sparsely observed in
humans but not in rodents. Protoplasmic astrocytes are the most
abundant glial cells in the cortex of humans and rodents, many
fold larger in humans than in rodent (Bushong et al., 2002; Ogata
and Kosaka, 2002), with extensive overlapping processes and
increased GFAP-immunoreactivity in their end feet. Similarly,
fibrous astrocytes in human white matter are larger than in
rodents (Oberheim et al., 2009).
To stir the complexity further, not all astrocytes are GFAP-
positive, confirming their phenotypic diversity in both species.
Using patch-clamp recordings and single-cell PCR reverse
transcription, transgenic mice with GFAP promoter-controlled
green fluorescent protein expression demonstrated two different
hippocampal astrocyte populations. One had thin and truncated
processes with attenuated GFAP immunoreactivity, while the
other showed more intense GFAP expression and processes
displayed intricate morphology with varied electrical properties
(Matthias et al., 2003). Furthermore, positron emission
tomography (PET) studies point to prevalent heterogeneous
binding to mitochondrial translocator protein (TSPO) ligands in
humans. Activated microglia and astrocytes overexpress TSPO
in normal elderly and demented subjects, however, individuals
can be classed as high or low (or mixed) affinity TSPO-binders
depending on the rs6971 polymorphism on the TSPO gene
(Owen et al., 2012).
In aged rats, neuronal iron revealed by Perl’s staining was
evident, particularly in the basal ganglia and hippocampus, in the
absence of a concomitant increase in ferritin immunoreactivity
in neurons (Benkovic and Connor, 1993). Similarly, increased
iron deposition with aging in wild-type mice was associated
with a decline in immuno-reactive ferritin suggestive of iron
dysregulation (Walker et al., 2016). Also, Parkinson’s disease
(PD) subjects showed increased iron deposition in neurons with
a concomitant decrease of ferritin-reactivity in the substantia
nigra, compared to that in neurons of age-matched healthy
aged humans (Connor et al., 1995). Iron dyshomeostasis with
aging may be due to an increase in iron that is not associated
with ferritin. As mentioned previously, excess iron may be
sequestrated by neuromelanin, protecting neurons against
toxicity, including from by-products of dopamine metabolism.
However, neuromelanin-containing organelles may then accrue
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high amounts of iron and neurotoxin overload with aging
and prime a neurodegenerative response (Zucca et al., 2015).
For example, leakage, or release of iron-laden neuromelanin
from degenerated neurons induces microglial activation, with
activated microglia in turn promoting neuronal death via release
of additional neuromelanin. This induces a self-propagating
mechanism of neuroinflammation and neurodegeneration,
contributing to the predisposition of elderly individuals to
neurodegenerative diseases.
Consistent with human studies, mice demonstrated
TfR1 immunoreactivity predominantly in neurons scattered
throughout the brain in gray matter regions (Moos, 1996;
Dickinson and Connor, 1998); strongest in cortical (particularly
pyramidal) neurons, hippocampal (Ammon’s horn and dentate
gyrus) neurons and cerebellar Purkinje cells (Dickinson
and Connor, 1998). TfR1 expression was virtually absent
in astrocytes, oligodendrocytes and microglia (Moos, 1996;
Dickinson and Connor, 1998). Summarizing the findings, iron-
rich oligodendrocytes does not exhibit TfR1 immunoreactivity
while neurons stained for TfR1 but showed poor iron staining in
rodents (Mash et al., 1990).
MECHANISMS UNDERLYING IRON
DYSREGULATION
Cytosolic Ferritin
The principle iron storage protein, ferritin, is comprised of heavy
(H) and light (L) chain monomers which co-assemble to form
heteropolymers of 24 subunits. Ferritin is able to carry up to
4,500 iron atoms to attenuate cytosolic and nuclear free labile
iron pools (Harrison and Arosio, 1996). The H-chain subunit,
owing to its ferroxidase activity, oxidizes Fe2+ to Fe3+ to enhance
iron sequestration by ferritin (Muhoberac and Vidal, 2013). On
the other hand, the L-subunit facilitates iron-core formation and
has a greater storage capacity than the H-subunit. In the brain,
H-chain ferritin predominates in neurons, while the microglial
and astroglial cells express mostly L-chain ferritin. Conversely,
oligodendrocytes contain both H- and L-subunits implying a
requirement of this glial cell to store and rapidly mobilize iron for
its cellular needs. The ratio of H- to L-chain is precisely regulated,
with even a small addition of mutant L-chain adequate to induce
dysfunction (Li et al., 2015). An autosomal dominant mutation
in the L-ferritin gene observed in congenital neuroferritinopathy,
a neurodegeneration disorder with brain iron accumulation
(NBIA), reduces iron incorporation into ferritin leading to an
increased labile iron pool, rendering the cell overtly sensitive to
oxidative damage (Levi et al., 2005). Similarly, L-ferritin variants,
460InsA and 498InsTC in HeLa and SH-SY5Y neuroblastoma
cells, respectively, show reduced ferritin functionality and
stability (Cozzi et al., 2010). The increase in cytosolic Fe2+
augments oxidative stress and leads to increased protein (and
lipid) oxidation, and may promote proteasomal impairment
and ferritin aggregate formation. Ferritin aggregates have been
observed to accumulate in the nucleus and cytoplasm of subjects
with neuroferritinopathy (Vidal et al., 2004) and in transgenic
mice harboring the 498InsTC mutation (Barbeito et al., 2009).
Evidence suggests that the pathogenesis of neuroferritinopathy
results from a combination of diminished iron storage function
and augmented neurotoxicity (Lee et al., 2006).
Ferritin Aggregates
Autophagy is the dominant process degrading cytosolic ferritin
and mitochondrial electron transport proteins in lysosomes,
liberating iron, and increasing cytosolic iron levels (Yu et al.,
2003). Protein aggregation is able to trigger autophagy (Grune
et al., 2004; Williams et al., 2006), tempting the postulation that
ferritin aggregates are a preliminary step to lysosomal uptake.
Electron microscopy of ferritin aggregates reveal the presence of
covalently-linked dimers, trimers, tetramers, extending to larger
oligomers (Harrison and Gregory, 1965; Williams and Harrison,
1968; Munro and Linder, 1978; Linder, 2013). The mechanism
underlying ferritin aggregation remains unclear, nevertheless,
ferritin oligomers bind to microtubules in a variety of cell lines
including mouse neuroblastoma cells in vitro (Hasan et al., 2005,
2006). The resultant microtubule-bound ferritin is 2.5 times
richer in iron than the unbound ferritin fraction. Further, when
mouse neuroblastoma become iron-deficient, ferritin oligomers
localized to dense microtubule neurite shafts but were absent
in the microtubule neurite-deficient tips. Microtubules appear
to act as a scaffold for the cytoplasmic distribution of ferritin
oligomers and aid transport of iron-rich ferritin, implicating
involvement of microtubules in iron metabolism (Hasan et al.,
2005, 2006). Moreover, the regional variability of iron in the
brain may be explained by lysosomes containing a range of iron
concentrations. More active lysosomes contain higher amounts
of iron and are more susceptible to oxidative stress (Nilsson
et al., 1997; Parente et al., 2012). This satisfactorily explains why
lysosomes of certain cells are resistant to substantial oxidative
stress while others succumb to apoptosis even in the presence of
a relatively low degree of stress (Antunes et al., 2001). Further,
treatment of lysosomes with deferoxamine protected against
hydrogen peroxide induced lysosomal rupture and apoptosis
(Kroemer and Jäättelä, 2005). This finding underscores the
detrimental effect of redox-active iron on lysosomal stability via
enhanced oxidative stress (Kurz et al., 2008).
Ferroptosis
An emerging process that is beginning to take center stage
is ferroptosis, a newly characterized form of iron-dependent
cell death distinct from apoptosis and necrosis (Dixon et al.,
2012; Yang and Stockwell, 2016; Angeli et al., 2017). Ferroptosis
is triggered by pharmacological impairment of anti-oxidant
systems involving glutathione and glutathione peroxidase
(GPX4) (Stockwell et al., 2017).
The glutamate/cystine antiporter (x−c ) exports cellular
glutamate in exchange for extracellular cystine. Once inside
the cell, cystine is converted to cysteine, a precursor of the
endogenous anti-oxidant, glutathione (Dixon et al., 2012).
Erastin and sorafenib, trigger ferroptosis via inhibition of x−c ,
depleting glutathione and inactivating GPX4 (Yang et al., 2014;
Stockwell et al., 2017). Ferroptosis may also be induced by
administration of GPX4 inhibitors, RSL3 and ML162. GPX4
catalyzes potentially toxic lipid hydroperoxides to non-toxic
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lipid alcohols (Yang et al., 2016) and its inactivation, whether
via glutathione depletion or direct GPX4 inhibition, induces
lipid peroxidation/oxidative stress, and eventually cell death.
Deferoxamine is able to prevent ferroptosis-induced cell death
through quenching of excess iron (Murphy et al., 1989; Cao and
Dixon, 2016). Furthermore, ferroptosis is regulated by genes
involved in iron metabolism via the Tf/TfR1 complex, IRP-2,
iron-sulfur cluster assembly enzyme, L-ferritin and H-ferritin
(Dixon et al., 2012).
The role of iron in ferroptosis is further substantiated
by holo-Tf but not apo-Tf, being essential for induction of
ferroptosis (Gao et al., 2015). Using gene silencing, size exclusion
fractionation and mass spectrometry, holo-Tf and glutamine
were shown to be required for ferroptosis, especially in the
presence of cystine deficiency due to impairment of the
glutaminolysis pathway (Gao et al., 2015). Indeed, silencing
TfR1 expression or administration of iron chelators inhibited
cell death, underscoring the requirement of holo-Tf import for
ferroptosis-induced cell death (Gao et al., 2015). In addition,
inhibition of lipid peroxidation either through genetic ablation
of Acyl-CoA synthetase long-chain family member 4 (ACSL4),
or pharmacological inhibition by lipo-oxygenase inhibitors,
ferrostatins or liproxstatins suppresses ferroptosis. Although
the physiological role of ferroptosis and the mechanisms
governing ferroptosis-induced cell death remain to be elucidated
(Stockwell et al., 2017), four processes are thought to be
critical for ferroptosis: (1) iron accumulation, (2) glutathione
depletion, (3) lipid peroxidation, and (4) membrane insertion of
phosphatidylethanolamines, all processes that enhance oxidative
stress (Bertrand, 2017; Doll et al., 2017; Kagan et al., 2017).
Genetic or pharmacological inhibition of any of these three
processes is sufficient to prevent ferroptosis (Dixon et al.,
2012; Cao and Dixon, 2016; Yang and Stockwell, 2016; Angeli
et al., 2017). Ferroptosis-mediated cell death appears to involve
synergistic interactions of iron toxicity, depletion of anti-
oxidant levels, insertion of phosphatidylethanolamines and lipid
membrane damage, leading to amplification of oxidative cell
damage in neurodegenerative diseases (Bertrand, 2017; Doll et al.,
2017; Kagan et al., 2017).
Preliminary evidence has shown that ferroptosis inhibition
can decrease the incidence of acquiring PD (Brauer et al.,
2015; Do Van et al., 2016; Guiney et al., 2017; Ito et al.,
2017). This has been investigated in a human dopaminergic
neuronal precursor derived cell line, LUHMES, which not only
exhibits unique sensitivity to ferroptosis but also recapitulates
several features of ferroptosis when exposed to erastin, including
glutathione depletion (Do Van et al., 2016). Deferiprone (an
iron chelator) and N-acetylcysteine (a precursor of glutathione
synthesis) was able to rescue these cells from erastin-induced
toxicity. The enhancement of erastin toxicity by elevated
dopamine was also shown to be rescued by ferroptosis
inhibitors (Do Van et al., 2016). Apparently, dopaminergic
neurons are inherently vulnerable to ferroptosis and could
offer an additional explanation to their heightened susceptibility
to neurodegeneration (Ayton et al., 2014). Moreover, pre-
treatment of mice with ferroptosis inhibitors was able to
rescue the behavioral impairment and neuronal loss due to 1-
methyl-4-phenyl pyridinium (MPP+) toxicity, an experimental
model of PD (Do Van et al., 2016). Ferroptotic damage after
ischemic stroke was observed in 12-month old tau-knockout
mice which display elevated brain iron (Tuo et al., 2017).
Normalization of iron levels by ceruloplasmin and amyloid
precursor protein (APP) ectodomain, or preventing ferroptosis
by liproxstatin-1, attenuated infarct size. On a similar note, tau-
knockout mice developed age-dependent brain atrophy, iron
accumulation and loss of nigral neurons, alongside cognitive
deficits and Parkinsonism (Lei et al., 2012). These pathological
and behavioral changes were rescued by oral treatment of tau-
knockout mice with an iron chelator, clioquinol. Tau expression
is an inhibitor of age-related brain iron accumulation and
demonstrates antagonistic pleiotropy as tau suppression in youth
is neuroprotective but exacerbates age-related neurotoxic iron
accumulation (Tuo et al., 2017).
Heme toxicity can be expressed in a plethora of ways;
via generation of superoxide and hydroxyl radicals; release
of redox-active iron; depletion of cellular stores of NADPH
and glutathione; and increased lipid peroxidation. Prolonged
exposure to hemoglobin and Fe2+ induces ferroptosis in
organotypic hippocampal slice cultures as confirmed by
the efficacy of ferroptosis inhibitors (Hahl et al., 2013).
Hemopexin, a glycoprotein, can bind heme with high affinity
and induce expression of heme-oxygenase 1 (HO-1) to confer
neuroprotection against heme and its downstream effects
(Hahl et al., 2013). Ferrostatin-1, a ferroptosis inhibitor,
attenuated hemoglobin-induced neuronal death and reduced
iron deposition in organotypic hippocampal slices (Li et al.,
2017). Similarly, ferrostatin-1 treated mice showed markedly
improved neurological function after intracerebral hemorrhage,
and other ferroptosis inhibitors (liproxstatin-1 and zileuton)
effectively reduced neuronal death (Li et al., 2017). Hemoglobin
also induced a dramatic increase in prostaglandin-endoperoxide
synthase 2, previously observed in erastin analogs and RSL3-
induced ferroptosis (Dixon et al., 2012; Yang and Stockwell,
2016), that was reversed by ferrostatin-1.
Autophagy may contribute to ferroptosis through selective
degradation of ferritin (ferritinophagy) and increasing the
labile iron pool, leading to accumulation of ROS and
ultimately driving ferroptosis (Gao et al., 2016; Hou et al.,
2016; Torii et al., 2016). The pathway is mediated by
nuclear receptor co-activator 4 (NCOA4, autophagy cargo
receptor) binding to ferritin in the autophagosome to deliver
ferritin to the lysosome for degradation with the release
of iron (Mancias et al., 2014). Genetic ablation of NCOA4
attenuated ferritin degradation and subsequent ferroptosis,
while forced NCOA4 expression induced ferritin degradation
and induced ferroptosis (Hou et al., 2016). The purpose of
the autophagic degradation of ferritin (aka ferritinophagy) is
to release iron during anemia for the crucial survival process
of erythropoiesis (Mancias et al., 2015). The dysregulation
of ferritinophagy may have detrimental consequences
to cell function mediated by ferroptosis in pathological
conditions.
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Lipofuscin
Lipofuscin is considered a hallmark of aging, showing a late
accumulation that inversely correlates with longevity (Brunk and
Terman, 2002; Terman and Brunk, 2004). Lipofuscin-associated
iron sensitizes lysosomes to oxidative stress, destabilizing
lysosome stability and inducing apoptosis via release of lysosomal
contents (Brunk and Terman, 2002; Terman and Brunk, 2004).
Similarly, chronic intracerebroventricular injections of ferrous
ammonium sulfate in 3–4 months old male CFY white rats
induced a 65% increase in the volume density of lipofuscin
in the parietal cortex and increased cerebral iron (Nagy et al.,
1985). Centrophenoxine (a cholinergic nootropic used as a
dietary supplement but also to treat symptoms of AD) pre-
treatment, not only prevented iron accumulation in rat cortical
synaptosomes following ferrous ammonium sulfate injection
into the CSF (Zs-Nagy et al., 1995) but also attenuated
lipofuscin deposition (Roy et al., 1983). Ultrastructural analyses
showed accumulation of lipofuscin granules associated with iron
deposits, particularly enriched in the cerebellum and striatum of
transgenic mice harboring a L-ferritin subunit mutation (498–
499InsTc mutation) (Maccarinelli et al., 2015). Collectively, the
data emphasizes that iron is sufficient to increase lipofuscin
formation possibly by increased iron-induced lipid peroxidation.
Hence, accumulation of iron-rich material, e.g., ferritin, resistant
to cellular degradation may enhance formation of lipofuscin.
Hemosiderin has been considered to be an unusually iron-rich
form of lipofuscin (Terman and Brunk, 2004; Kurz et al., 2008)
as well as a denatured form of H-ferritin (Miyazaki et al., 2002).
Hydrogen peroxide, a by-product of mitochondria respiration,
levels of which increase with age, may diffuse into iron-laden
lysosomes and enhance lipofuscin formation, with lipofuscin
possibly providing a catalytic surface for the Fenton reaction.
The low pH and highly reductive environment of the lysosome
favors rapid reduction of Fe3+ to Fe2+ (Schafer and Buettner,
2000; Kurz et al., 2011). Mitochondria also contain ferritin
which can undergo autophagocytic degradation to provide an
additional source of free iron to further enhance production of
ROS (Eaton and Qian, 2002). The accretion of iron-catalyzed
oxidative stress induces peroxidative damage of lysosomes and
membrane permeability is increased, leading to iron leakage
which in turn augments the labile iron pool (Eaton and Qian,
2002). Oxidative stress initiates a cascade of events, culminating
in the formation of lipofuscin-containing aggresomes.
Mitochondrial Ferritin
Mitochondrial ferritin displays high sequence homology to
cytosolic H-ferritin (Levi et al., 2001) and helps to regulate iron
distribution between the cytosol and mitochondria to attenuate
ROS-generation. Mitochondrial ferritin has been associated with
an anti-oxidative (neuroprotective) effect in neurodegenerative
diseases including AD and PD cells (in vitro) and mouse models
(Wu et al., 2013; Arber et al., 2016; Guan et al., 2017). Ten-
month old mitochondrial ferritin knock-out (KO) mice infused
with Aß25−35 had exacerbated learning and memory impairment
compared to wild-type counterparts, and augmented apoptosis
(reflected by decreased Bcl-2/Bax ratio) in the hippocampus
(Wu et al., 2013; Wang et al., 2017). The increase in neuronal
apoptosis was concomitant with augmented hippocampal levels
of L-ferritin and Fpn but decreased TfR1 expression (Wang et al.,
2017). It is likely that inhibition of IRP binding underlies the
reported biochemical changes due to an increased regulatory iron
pool in neurons challenged with Aß (Lane et al., 2015). The levels
of malondialdehyde (MDA), a product of lipid peroxidation
and a surrogate for oxidative stress were also significantly
increased (Wang et al., 2017). Remarkably, overexpression
of mitochondrial ferritin restored concentrations of iron and
its metabolizing proteins, reduced oxidative damage via the
p38 mitogen-activated protein kinase (MAPK) and activated
extracellular signal-regulated kinase (Erk) signaling (Wu et al.,
2013). These findings point to mitochondrial ferritin being
pivotal for labile iron pool regulation to limit oxidative stress and
neurodegeneration in aging and AD (Valko et al., 2016).
Iron Dyshomeostasis and
Neuroinflammation
The neuroglia (astrocytes and microglia), play an essential role
in maintaining brain iron homeostasis to modulate neuronal
activity and regulate neuroinflammation (Pelizzoni et al., 2013).
Iron has been shown to stimulate microglia, increasing activation
of NFκB and production of pro-inflammatory cytokines
(Saleppico et al., 1996). Ferrocene supplementation led to
1.4-fold increase in ferritin transcripts predominantly in the
microglia and oligodendrocytes of organotypic hippocampal
slices, accompanied by significant loss of olig2-positive cells
and increased activated microglia (Healy et al., 2016). Increased
release of IL-1ß and TNFα by iron-laden microglia induced
upregulation of IRP1, DMT1, hepcidin and TfR1-1 expression in
ventral mesencephalic neurons via production of ROS (Xu et al.,
2016).
Conversely, neuroinflammation induced by stereotactic
injection of LPS into the striatum, not only induced microglial
activation but also ferritin expression and total nigral iron
content in aged rats (Hunter et al., 2008). Interestingly,
cytokine treatment (TNFα, IL-6 and LPS) stimulated DMT1
expression and accompanying downregulation of Fpn expression
in neurons, astrocytes and microglia (Urrutia et al., 2013).
Hepcidin secreted by astrocytes and microglia seems to be
the phenomenon underlying inhibition of Fpn expression
under conditions of inflammatory milieu. The cumulative
effect of these changes is iron accumulation in neurons and
microglia but not in astrocytes (see below). Deferoxamine
reversed LPS-induced downregulation of Fpn and increased
ferritin in the hippocampus (Zhang et al., 2015). Accordingly,
deferoxamine has been shown to attenuate cognitive deficits
in AD (Crapper McLachlan et al., 1991) and PD subjects
(Ward et al., 2014). Moreover, deferoxamine counteracted
LPS-induced hippocampal microglial activation and associated
pro-inflammatory (TNFα and IL-1ß) cytokine production,
caspase-3 mediated apoptosis and ameliorated memory
impairment in mice (Zhang et al., 2015). Iron appears to have
a role in the upregulated MDA expression (increased ROS) and
downregulated SOD activity (decreased antioxidant activity)
in LPS-induced neuronal injury and cognitive impairment.
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Iron can activate GSK-3ß, a downstream target of Akt involved
in regulation of important cellular brain processes and is a
positive regulator of inflammation (Martin et al., 2005; Zhang
et al., 2015). Overexpression of GSK-3ß leads to apoptosis
and a decline in the number and volume of postsynaptic
hippocampal granular neurons, changes putatively linked to
cognitive impairment. Interestingly, intracerebroventricular
injections of LPS reduced the phospho-GSK3ß/GSK3ß ratio in
the hippocampus resulting in abnormal activation of GSK-3ß
(Zhang et al., 2015). Deferoxamine was able to attenuate GSK-3ß
phosphorylation, in turn downregulating caspase-3 mediated
apoptosis in the LPS-exposed mouse brains. On a different note,
deferoxamine has been shown to downregulate levels of NADPH
oxidase subunits (gp91phox) which are able to precipitate
oxidative stress (Li et al., 2016). Also, deferoxamine can inhibit
p38 MAPK activation and is associated with reductions in pro-
inflammatory cytokines. Anti-inflammatory drugs had a similar
effect to chelation therapy, reversing iron-induced synaptic
loss, apoptosis, and impairment of mitochondrial dynamics in
rodents exposed to iron overload (Nagarkatti et al., 2009; da Silva
et al., 2014; Lavich et al., 2015).
The positive feedback loop between neuroinflammation
and iron accumulation contributes in a progressive manner
to promote neurotoxicity. Based on the precept that iron
dysregulation enhances ROS generation and cellular damage,
alterations in proteins involved in iron regulation amplifies iron-
dependent oxidative stress contributing to neurodegeneration.
The different lines of evidence emphazise the intimate
relationship between iron accumulation, neuroinflammation
and cognition in physiological and detrimental aging.
Astrocytes appear to be more resilient to iron accumulation
owing to their GPI-anchored ceruloplasmin, responsible
for oxidizing Fe2+ to Fe3+, enabling Fpn-mediated cellular
iron export (De Domenico et al., 2007). GPI-ceruloplasmin
aids localization of Fpn to the cell membrane for optimal
functioning (De Domenico et al., 2007). The importance
of ceruloplasmin in regulating the labile iron pool and
contributing to anti-oxidant defense is underscored by findings
in aceruloplasminaemia subjects. The GPI-ceruloplasmin
deficiency in aceruloplasminaemia impairs cellular iron egress,
resulting in widespread brain iron accumulation particularly
in the basal ganglia leading to neurodegeneration and motor
deficits (Xu et al., 2004; Ward et al., 2014).
Experimental evidence suggest the choroid plexus has the
capacity to sequester metals including iron as an essential CNS
defense mechanism (Zheng, 2001). The epithelial cells of the
choroid plexus synthesize iron-associated proteins including
ceruloplasmin (Aldred et al., 1987). Tf is also secreted by the
choroidal epithelial cells (Aldred et al., 1987), which may bind
Fe3+ and drain iron from the CSF possibly via the glymphatic
system. Intriguingly, the choroid plexus from older wild-type
mice and human post-mortem samples demonstrated increased
transcript expression of type I interferons, i.e. upregulated
neuroinflammation (Baruch et al., 2014). CSF acquired from
22-month old wild-type mice, used to incubate primary cultures
of young (3-month old wild-type mice) choroidal epithelial
cells, augmented type I interferon transcripts. CSF injection
of antibodies against the type I interferon receptor in aged
mice rescued memory deficits, attenuated neuroinflammation
and restored neurogenesis to the levels seen in young mice
(Baruch et al., 2014). Apparently, the choroidal epithelium
undergoes dynamic changes during aging and dementia with
reduced ability of the choroid plexus to regulate brain interstitial
fluid (Serot et al., 2003; Wyss-Coray, 2016), promoting a
pathological oxidative CSF environment. Accordingly, the
ferroxidase activity of soluble ceruloplasmin in the CSF is
significantly attenuated in PD patients (Barbariga et al., 2015).
Ceruloplasmin oxidation promotes asparagine deamidation,
a spontaneous reaction that happens during protein aging
to form aspartate and iso-aspartate. Deamination of specific
asparagine-glycine-arginine motifs of ceruloplasmin are in turn
able to attenuate ceruloplasmin activity. Protein deamination
is associated with greater integrin-binding and intracellular
signaling (Erk1/2, Akt and MAPK) that may contribute to iron
dysregulation via modified gene activation, cell proliferation
and re-arrangement of the actin cytoskeleton (Barbariga et al.,
2015). Interestingly, deamidation-mediated protein aggregation
has been reported for α-synuclein in PD (Vigneswara et al.,
2013), Aβ and tau in AD (Shimizu et al., 2000). The oligomers
in combination with iron dyshomeostasis may propagate disease
further in PD and AD. Idiopathic PD subjects showed ∼80%
loss of ceruloplasmin ferroxidase activity in the substantia
nigra, which contributes to the accumulating pro-oxidant iron
characterizing PD pathology (Ayton et al., 2013). As proof of
concept, peripheral infusion of ceruloplasmin attenuated nigral
iron accumulation and neurodegeneration in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model for PD.
Also, ceruloplasmin-knockout mice developed Parkinsonism
that was reversed by iron chelation (Ayton et al., 2013). It is
important to emphazise that CSF/plasma levels of ceruloplasmin
(and ferritin) may not be altered in PD and AD but their
functional status may be altered (Kristinsson et al., 2012).
Adult ceruloplasmin null-mice demonstrate increased iron
deposition in widespread regions of the brain including
in the cerebellum and brainstem (Cui et al., 2009). The
striatum characteristically exhibits iron accumulation in subjects
with aceruloplasminaemia but shows normal iron levels in
ceruloplasmin KO mice. This discrepancy perhaps reflects the
shorter lifespan of mice compared to humans. More importantly,
the regional variability in iron load in ceruloplasmin null-
mice is due to hephaestin expression, another multi-copper
oxidase, and a homolog of ceruloplasmin. Hephaestin levels are
significantly elevated in the cerebral cortex and striatum of 80-
week old ceruloplasmin KO mice relative to wild-type mice
(Cui et al., 2009). On the other hand, hephaestin expression
was slightly attenuated in the substantia nigra and cerebellum
with relatively unchanged levels in the hippocampus. Apparently,
the augmented hephaestin levels compensates for the loss of
ceruloplasmin so as to maintain normal iron concentrations
in select regions such as the cerebral cortex and the striatum.
Hephaestin KO mice exhibit significantly increased iron and L-
ferritin in the mouse brain cortex, hippocampus, brainstem, and
cerebellum compared to ceruloplasmin KO and wild-type at 6
months of age (Jiang et al., 2015). Ablation of the multi-copper
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oxidases, ceruloplasmin, and hephaestin, leads to deregulated
brain iron homeostasis in mice and present useful models for
exploring neurodegenerative diseases (Cui et al., 2009; Jiang et al.,
2015).
NEUROIMAGING PERSPECTIVE ON IRON
DEPOSITION
The advent of neuroimaging has provided the unprecedented
opportunity to study age-related changes in vivo, and evaluate
efficacy of therapeutic strategies. Paramagnetic properties
exhibited by iron render magnetic resonance imaging (MRI)
a promising tool to evaluate brain iron content as iron
deposition induces changes in the transverse relaxation time (T2)
(Daugherty and Raz, 2015). Iron can also induce local magnetic
susceptibilities and reduce T2∗. Histological data suggests ferritin
and hemosiderin (and neuromelanin in substantia nigra) are the
only paramagnetic agents expressed at sufficient concentrations
to affect the brainMRI signal (Schenck, 1995). Estimated binding
of non-heme iron to ferritin in physiological conditions is
90%, while concentrations of Tf-bound iron or the putatively
pathogenic pool of labile free iron is low (Moos, 2002; Haacke
et al., 2005).
Meta-analysis of twenty MRI studies involving healthy aged
subjects reported similar age-related iron changes in the globus
pallidus to post-mortem findings (Daugherty and Raz, 2013).
Though iron deposition was found to be elevated in subcortical
nuclei, the globus pallidus emerged with the highest iron
content with age, preceded by the striatum, red nucleus, and
substantia nigra (Acosta-Cabronero et al., 2016). Cross-sectional
neuroimaging studies suggest a significant, albeit smaller, positive
correlation between age and iron deposition in the thalamus
and hippocampus. Much of the age-related trajectory evidence
has originated from cross-sectional data and may not capture
the dynamics of the intricate aging process. On the other
hand, longitudinal assessments can help evaluate the key role
of a plethora of mediators in age-related associations between
brain and cognitive performance. Using R2∗ (reciprocal of T2∗)
relaxometry, a longitudinal study demonstrated higher baseline
iron deposition in the striatum predicted worsening of working
memory after 2 years (Daugherty et al., 2015). This finding was
replicated in an independent sample of older adults with multiple
measurements performed over a period of 7 years (Daugherty
and Raz, 2015, 2016). Potentially, brain iron deposition may be
a biomarker of cognitive decline in normal aging.
Increased R2 (reciprocal of T2) and R2∗ signal (reflective
of iron accumulation) was observed in mice during the
course of normal aging (2–27 months) in the basal ganglia
(Walker et al., 2016). R2 and R2∗ correlated well with iron
content measured using synchrotron-based X-ray fluorescence
iron mapping. The iron accumulation was concomitant with
increased ferritin immunoreactivity in all basal ganglia regions
except the substantia nigra. The discordance between iron and
ferritin upregulation is indicative of iron dyshomeostasis in
the aged substantia nigra. Moreover, nigral neurons has been
shown to be more susceptible than hippocampal or cortical
neurons to LPS-induced neurodegeneration and oxidative stress
(Bartzokis et al., 2004; van Rooden et al., 2015). Furthermore,
the substantia nigra, already abundant in microglia, exhibits
microgliosis, and astrogliosis with aging. The iron dysregulation,
alongside microgliosis, and astrogliosis, as well as the known
high metabolic activity of nigral neurons (Crichton et al., 2011;
Ward et al., 2011; Walker et al., 2016), together may explain
the particular vulnerability of the aged substantia nigra to
neuropathology. Interestingly, dietary restriction (intermittent
fasting), a robust “anti-aging” regimen in rodents, attenuated age-
related in vivo R2 increases in the substantia nigra of aged mice
suggesting some restoration of age-associated iron dysregulation
(Walker et al., 2016).
AD
A longitudinal MRI study conducted in a transgenic mouse
model of amyloidosis (12–18 months) found increased amyloid
plaque formation coincided with an augmented R2 in the
hippocampus and cerebral cortex (Braakman et al., 2006).
This observation is consistent with MRI human findings,
where elevated iron levels in the hippocampus were negatively
correlated with cognitive performance assessed by the mini-
mental state examination (MMSE) (Zhu et al., 2009; Raven
et al., 2013; Langkammer et al., 2014). Interestingly, iron is
associated with Aß plaque formation and a constituent of core
and halo plaques (Everett et al., 2014), with Fe3+ bound to
Aß being reduced to Fe2+ and promoting ROS production.
The pro-oxidant environment escalates the production of Aß
oligomers/plaques via enhanced amyloidogenic processing of
APP (mediated by ß-secretase) (Everett et al., 2014; Peters
et al., 2015). An in vivo study demonstrated iron overload in
APP/PS1 (amyloidosis) mouse model stimulated amyloidogenic
processing and altered neuronal signaling to increase Aß
plaque formation, leading to cognitive deterioration (Becerril-
Ortega et al., 2014). Although some report unaltered total
brain iron contents in AD, nonetheless, microscopic focal iron
deposits are found either in the plaque core or in the vicinity
(Langkammer et al., 2014). PET-ligand ([11C]-PIB), specific
to fibrillary Aß plaques (Nordberg, 2004), was found to be
significantly associated with higher cortical iron (as revealed by
quantitative susceptibility mapping which is sensitive to iron-
induced changes in susceptibility) in Aß-positive cognitively
normal, MCI and AD (van Bergen et al., 2016; Ayton et al.,
2017b), and synergistically exacerbated cognitive performance.
This is consistent with increased iron deposition coinciding with
early plaque formation in a mouse model of AD (Leskovjan et al.,
2011). High CSF ferritin (used as a proxy measure for iron load)
was significantly associated with accelerated depreciation of CSF
Aß, implying facilitation of Aß deposition in AD (Ayton et al.,
2017a). Strikingly, the high CSF ferritin progressed transition
from threshold preclinical Aß levels to the average level of AD
from approximately eighteen to 10 years. The different lines
of evidence suggest that disease progression is conferred by
spatial colocalization of iron with Aß deposition, and confirms
an association between increased brain iron load and AD.
The onus is being placed on identifying the cellular
localization of iron to investigate which cells (glia or neuron)
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specifically accumulate iron with aging. Adopting this approach,
focal MRI hypo-intensities were identified in the hippocampus,
predominantly in the subiculum of AD subjects at post-mortem
(Zeineh et al., 2015). Co-registration of ex vivo MRI with
histology enabled localization of the MRI-detected iron deposits
to (CD163-identified) activated microglia. The subiculum is an
important structure via which entorhinal perforant and alvear
pathway neurons travel to the hippocampus. The identified iron
deposition associated with microglial activation may augment
entorhinal neurodegeneration, known to be affected early on in
AD. The microtubule associated protein tau is also observed
in the subiculum. These findings provide an incentive to
monitor progression of iron deposition and neuroinflammation
with particular relevance to their association with Aß and tau
pathology.
Total levels of CSF ferritin were unaltered when comparing
cognitively normal, MCI, and AD subjects in the Alzheimer’s
disease neuroimaging initiative (ADNI) cohort (Ayton et al.,
2015a). Nevertheless, CSF ferritin was shown to predict cognitive
outcomes over a period of 7 years. MCI subjects with high ferritin
levels demonstrated an earlier age of diagnosis (Ayton et al.,
2015a), consistent with previous reports, where an earlier age of
onset of AD is associated with greater neocortical iron burden
as assessed by MRI in vivo (Bartzokis et al., 2004; van Rooden
et al., 2015). In addition, high CSF ferritin load in MCI subjects
was associated with MRI-assessed hippocampal atrophy and AD
biomarkers (Ayton et al., 2015a). It would be interesting to
determine the association of other CSF proteins involved in iron
metabolism (including ceruloplasmin, transferrin) and evaluate
them as predictors of conversion of subjects to AD.
PD
PD is characterized by classical iron accumulation in the
substantia nigra and basal ganglia that appear hypointense on
a T2∗-weighted MRI in vivo (Pyatigorskaya et al., 2014). The
increased iron content observed in the aforementioned regions
correlates with severity of cognitive and motor impairments
(Atasoy et al., 2004). Likewise, a new genetic mouse model of PD,
demonstrated reduced T2∗ of the substantia nigra and striatum
indicative of abnormal iron load and associated with motor and
cognition deficits (Cong et al., 2016). Interestingly, augmented
iron load (reduced T2∗) in the substantia nigra preceded motor
symptoms in PD subjects (Martin et al., 2008; Wallis et al., 2008;
Du et al., 2011; Ulla et al., 2013; Aquino et al., 2014; Devos
et al., 2014; Hopes et al., 2016). Iron accumulation increased
rapidly over the first 3–5 years of PD but progressed much more
insidiously in advanced stages (Hopes et al., 2016). Iron overload
showed a higher degree of correlation with motor symptom
severity at earlier stages of the disease, while lack of correlation
was observed at later stages of PD. MPTP-intoxicated mice
exhibited iron overload (decreased T2∗) only 7 days after MPTP
administration, recapitulating the results obtained in PD patients
(Hopes et al., 2016). In another study, increased nigral iron
content precipitated oxidative stress and dopaminergic neuronal
death in a MPTP-induced PD mouse model, further reinforcing
T2∗ as an early, sensitive biomarker with translational potential
(You et al., 2015). Moreover, iron content in the substantia nigra
and locus coeruleus is substantially increased in PD subjects, and
loss of nigral neurons in particular leads to a substantial reduction
of neuromelanin (Wang et al., 2016a). Since neuromelanin can
chelate iron and thought to prevent toxic accumulation of iron
(Zecca et al., 2008b), a reduction in neuromelanin content may
explain the increase in labile iron pool. The free iron may exceed
the iron-binding capacity of ferritin as well as bind to Lewy bodies
(Castellani et al., 2000), increasing neuronal and glial toxicity via
oxidative stress (Griffiths et al., 1999).
Recently, a handful of studies have demonstrated MRI T1-
weighted fast spin echo appeared to identify neuromelanin
(Sasaki et al., 2006). The hyperintense T1-signal of the substantia
nigra corresponded histologically to neuromelanin-containing
neurons (Kitao et al., 2013). In PD, this neuromelanin signal
in the substantia nigra and locus coeruleus attenuates with
disease progression (Schwarz et al., 2011; Ogisu et al., 2013;
Reimão et al., 2015). A greater reduction in T1-weighted signal
was also observed in the lateral segment of the substantia
nigra with relatively preserved medial aspect, in agreement with
the reported pathological characteristics of neuronal atrophy
in PD (Miyoshi et al., 2013). MRI-detected neuromelanin
measurements have demonstrated high sensitivity and specificity
for differentiating between healthy controls and PD subjects
(Miyoshi et al., 2013). MRI offers high diagnostic accuracy also
at early stages of disease, only slightly less than with [123I]-FP-
CIT-SPECT studies. A greater reduction in the neuromelanin
signal is observed in advanced PD compared to early stages
(Schwarz et al., 2011). A gradual and stage-dependent decrease
in neuromelanin in the medial substantia nigra was indicated by
T1-weighted MRI in PD subjects, with pronounced reduction of
neuromelanin in the locus coeruleus in later stages, suggesting
alterations commence ventrolaterally, and extendmedially in PD.
Thus, MRI measurements, thought to be of neuromelanin, may
be useful for monitoring disease progression.
The tau tangle PET ligand, [18F]-AV-1451 ([18F]-T807),
exhibits off-target binding to neuromelanin in the midbrain,
and is proposed as a measure of the pigmented dopaminergic
neuronal count in the substantia nigra (Hansen et al.,
2016). Interestingly, off-target AV-1451 binding patterns (using
autoradiography) observed in the basal ganglia correspond with
Perl’s staining, suggesting AV-1451 associate with iron. High AV-
1451 binding in the substantia nigra is consistent with the high
iron content in this region. The high binding avidity of AV-1451
to the substantia nigra, even in subjects with no tau pathology,
argues for its potential binding to iron (Lowe et al., 2016).
However, significant Perl’s staining for iron evident in the globus
pallidus of a NBIA case did not coincide with AV-1451 binding
pattern, suggesting that the off-target moiety for this tracer is
neuromelanin (Lowe et al., 2016). Future cross-validation MRI-
PET studies are warranted to validate the prognostic value of
neuromelanin-sensitive MRI and AV-1451.
GENETIC REGULATION OF
IRON-ASSOCIATED PROTEINS
Brain iron homeostasis is regulated by IRPs, IRP1, and IRP2
(Rouault, 2006) (Figure 5). When cellular iron is high, IRP bind
to the IRE of transferrin receptor and DMT1 mRNAs, decreasing
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FIGURE 5 | IRE/IRP regulation of ferritin and transferrin receptor. Proteins involved in the storage, export and uptake of iron are regulated via the interaction of
iron-regulatory proteins (IRPs) with iron-responsive element (IREs), conserved RNA secondary structures (Rouault, 2006; Leipuviene and Theil, 2007). In conditions of
low iron, IRP binds to a single IRE in the 5′-untranslated region (UTR) of ferritin mRNA to suppress their translation, while IRP binding to multiple IREs in the 3′ UTR of
transferrin receptor-1 (TfR1) which stabilizes the mRNA for TfR1 synthesis. When the iron content in the cell is high, the lack of IRP-binding leads to increased
synthesis of ferritin and destabilization of TfR1 mRNA.
their translation, resulting in attenuated cellular uptake of iron.
Conversely, when cellular iron levels are low, IRPs binds to the
IRE situated at the 3′-UTR of transferrin receptor and DMT1
mRNAs, stabilizing them and increase their cellular expression
level, augmenting iron uptake. Also IRP bind to IREs of
ferritin and Fpn mRNAs, rendering them unstable and lowering
protein expression (Leipuviene and Theil, 2007), effectively
preventing iron sequestration by ferritin or cellular iron export
by Fpn, maintaining iron homeostasis. Interestingly, mice with
genetic ablation of IRP1−/− do not exhibit neurodegeneration
as IRP1 minimally contributes to iron regulation in the
wild-type (LaVaute et al., 2001). However, IRP2-null mice
demonstrate significant iron deposition in white matter tracts
and many brain nuclei, particularly in the striatum, thalamus,
cerebellum and colliculi. Ferritin (iron) accumulates abnormally
in neuronal and oligodendroglial populations particularly in the
striatum and the thalamus (LaVaute et al., 2001). The severe
iron dyshomeostasis leads to neurodegeneration in adulthood
followed by development of motor symptoms in the form
of ataxia, bradykinesia and tremor (LaVaute et al., 2001;
Smith et al., 2004). Interestingly, pronounced worsening of
the neurodegeneration was evident in IRP1+/− IRP2−/− mice
relative to IRP1+/+ IRP2−/− mice, suggesting loss of one IRP1
allele further aggravates iron metabolism, and predominantly
affecting the substantia nigra. Additionally, activated microglia
were associated with neurodegeneration, implying a role for iron
deposition in fuelling neuroinflammation (Smith et al., 2004).
The interesting finding of APP and prion protein (PrP) as
physiological regulators of iron homeostasis puts AD and prion
diseases in the limelight (Singh et al., 2009; Singh, 2014). Iron
putatively modulates APP processing via interaction of IRP
with IRE in the 5′-UTR of its mRNA, positioned immediately
upstream of an interleukin-1 responsive acute box domain
(Rogers and Lahiri, 2004; Bandyopadhyay and Rogers, 2014).
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Under conditions of low iron as observed with the use of
iron chelators (Rogers et al., 2002), IRP1 may bind to the
IRE of APP with high affinity to repress APP translation.
Conversely, high iron load likely upregulates APP translation
and increases the amyloidogenic processing of APP yielding
Aß species. Meanwhile, increased interleukin-1 may increase
IRP binding to APP decreasing APP production (Rogers and
Lahiri, 2004; Bandyopadhyay and Rogers, 2014). Interestingly,
decreased APP expression in nigral dopaminergic neurons of
human PD cases was observed, and likewise APP-knockout mice
developed iron-mediated nigral cell loss (Ayton et al., 2015b).
The augmented nitric oxide (NO) was shown to suppress APP
translation in MPTP PD mouse models pinpointing NO toxicity
as a mechanism for causing iron-dependent neurodegeneration
in PD. On the other hand, APP-overexpressing mice were
immune to MPTP toxicity. Moreover, a putative IRE in the
5′-UTR of mRNA encoding the 140-residue α-synuclein has
been reported (Friedlich et al., 2007), suggesting that this RNA
structure post-transcriptionally controls α-synuclein production
in response to cellular iron.
APP has been suggested to possess ferroxidase activity to
aid cellular iron export but supporting evidence is lacking.
APP knockout mice demonstrate markedly increased iron in
the brain and several other organs (Duce et al., 2010). It is
likely that the neuroprotective properties of APP are conferred
by soluble APPα, a cleavage product of non-amyloidogenic
pathway, as a point mutation within the REXXE motif nullifies
its neuroprotection properties (Duce et al., 2010). Emerging
evidence suggests that the endogenous APP stabilizes Fpn in
the neuronal membrane, supporting its role in iron export from
neurons (Wong et al., 2014).
Interestingly, IRP-IRE binding activities together with ferritin
were found to be increased in the astrocytes of hippocampus
and cerebral cortex in PrPSc (scrapie form of PrP, a ß-sheet
rich insoluble conformer) mice (Kim et al., 2007). Moreover,
PrPc (native form of PrP) is a ferrireductase, facilitating influx
of iron by TfR1 and enhancing non-Tf bound iron uptake via
DMT1 and the Zip Fe/Zn transporter (latter, independent of TfR1
activity). PrPc is highly expressed in neurons and low in glial cells
(Singh et al., 2009). Taken together, iron dysregulation appears
to be a common theme prevalent in the etiology/pathogenesis of
neurodegenerative diseases.
EFFECT OF SYSTEMIC IRON OVERLOAD
ON BRAIN IRON
Hereditary hemochromatosis caused by mutations in the
HFE gene (C282Y and H63D being the most common
polymorphisms) is characterized by excessive dietary iron
absorption and accumulation in various organs of the body
(Nandar and Connor, 2011). Most particularly, liver iron
deposition causes fibrosis and cirrhosis (Banerjee et al., 2014) but
the effect of systemic iron on the brain remains elusive. HFE is
a membrane protein implicated in controlling iron absorption
via regulation of the affinity of TfR1 for holo-Tf. Although
a link between HFE mutation and iron abnormalities in the
framework of developing AD has been postulated (see below),
studies investigating the brain effects of HFE dysfunction are
sparse in humans. However, some important advances have been
made using HFE knockout and knock-in mouse models.
Male HFE knockout mice at 3 months of age experienced
motor coordination deficits but these behavioral manifestations
were not paralleled by brain iron accumulation (Golub et al.,
2005). Also, rat models of dietary iron overload demonstrate
behavioral disturbances without obvious elevation in brain iron
(Sobotka et al., 1996). Likewise, an H67D knock-in mouse
line (equivalent to human homology of H63D) did not exhibit
significant increases in total brain iron concentration but iron-
related proteins were significantly changed (Nandar et al., 2013).
Increased expression of HFE and H-ferritin was observed in 6-
month old H67D mice, alongside astrogliosis, increased protein
oxidation, expression of x−c and HO-1, suggestive of heightened
metabolic and oxidative stress. Accordingly, the striatum of
HO-1 knockout mice was protected from iron-mediated injury
in males but not females (Wang et al., 2016b). Meanwhile,
H67D mice at 12-months had augmented H- and L-ferritin
accompanied by attenuated Tf expression, indicating increased
storage of iron (Nandar et al., 2013). The accruing oxidative
stress is attenuated by increased iron storage in microglia (L-
ferritin positive). Interestingly, no astrogliosis or oxidative stress
was observed at 12-months, attenuation of the latter process
may be explained by significant increments in nuclear factor E2-
related factor 2 (Nrf2) and compensatory increased expression
of anti-oxidant enzymes. Furthermore, DMT1 levels were also
significantly decreased in 6-month old H67D, lower in the cortex,
striatum, and cerebellum compared to wildtype mice (Nandar
et al., 2013). DMT1 is responsible for endosomal iron export, its
downregulation decreases cellular iron availability. At the cellular
level, human neuronal cell lines harboring H63D polymorphism
demonstrated a higher labile iron pool, increased oxidative stress,
altered glutamate homeostasis, chemokine secretion, and tau
hyperphosphorylation (Nandar and Connor, 2011). Indeed, the
H63D polymorphism is frequently observed in AD subjects
(Sampietro et al., 2001; Ali-Rahmani et al., 2014) and is
considered a risk factor for neurodegenerative diseases.
Systemic iron overload levels may indirectly affect the brain.
For instance, high systemic iron can cause severe liver damage
resulting in accrual of toxic substances such as ammonia
in the blood. Ammonia being a toxic gas, freely diffuses
across the BBB and hyperammonaemia leads to speech and
motor impairment, seizures and coma (Bridle et al., 2003;
Eroglu and Byrne, 2009; Cordoba, 2014). Interestingly, the
importance of ammonia is underscored by its excessive formation
in brains of AD subjects, and elevation of blood ammonia
concentrations (Seiler, 2002). Ammonia exerts neurotoxicity via
modulation of neuroinflammation, mitochondrial dysfunction,
altered glutamate/GABA neurotransmission, these perturbations
are manifested clinically in the form of cognitive decline
(Adlimoghaddam et al., 2016). Phenylbutyrate, an ammonia
quencher, was able to rescue learning deficits due to clearance of
intraneuronal Aß and restoration of dendritic spine densities of
hippocampal CA1 pyramidal neurons to control levels in Tg2576
mice (Ricobaraza et al., 2012). Likewise, phenylbutyrate protected
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dopaminergic neurons in the MPTP mouse model of PD via
anti-inflammatory and anti-oxidant activity (Roy et al., 2012).
Iron overload has been shown to cause low-grade
inflammation in the liver, and resulting alterations in circulating
cytokines and immune cells may affect the brain without
increases in total brain iron (Bridle et al., 2003; Eroglu and
Byrne, 2009; Cordoba, 2014). Indeed, systemic inflammation
has been postulated to be involved in the pathogenesis
of neurodegenerative diseases, by further exacerbating
neuroinflammation (Perry et al., 2003).
A number of studies have evaluated alterations in brain iron
concentration in response to iron supplementation at various
ages. Neonatal excess iron supplementation augmented iron
load in the basal ganglia at 3-month old mice, accompanied
by impaired performance in radial arm maze learning tests and
had poor spontaneous motor behavior (Schröder et al., 2001).
Impaired recognition memory was also observed and reversed
by selegiline, a monoamine oxidase inhibitor, and desferoxamine.
Administration of iron as early as postnatal days 5–7, or as
late as days 19–21 in rats, induced oxidative stress in the
hippocampus, cortex, and substantia nigra (Dal-Pizzol et al.,
2001). Furthermore, iron administration for three consecutive
days (postnatal days 12–14) in neonatal rats led to increased
apoptotic markers (caspase-3 and Par4) in the hippocampus and
cortex of adult rats (Miwa et al., 2011). GFAP-labeled astrocytosis
was increased in the hippocampus of 3-month old rats treated
with iron between postnatal days 12 and 14, and in the substantia
nigra and striatum of 2-year old iron-treated rats (Fernandez
et al., 2011). The prevailing evidence suggests that dietary iron
supplementation early in neonatal period is associated with
cellular imprinting in the brain at a later stage in life.
Male weanling rats fed an excess iron supplemented diet
for 6 or 8 weeks demonstrated significant iron load in the
cortex, hippocampus, substantia nigra, and striatum (Chang
et al., 2005; Ke et al., 2005; Qian et al., 2007). Moreover, 8 week
supplementation with ferrocene from aged 4-weeks in male and
female mice, led to an 8-fold increase in liver iron (Malecki
et al., 2002). L-ferritin and HO-1 (indicators of increased iron)
were elevated in the striatum while the iron concentration
was increased in the cerebrum. Intraperitoneal injection of
Fe2+ sulfate in adult rats for five consecutive days resulted
in impaired emotional behavior and spatial learning (Maaroufi
et al., 2009), with associated with significant iron accumulation
in the hippocampus and basal ganglia.
In summary, small rodent studies have shown that peripheral
iron administration/excess iron supplementation may lead to
iron accumulation in the brain andmediate brain dysfunction via
oxidative stress, induced neuroinflammation and apoptosis, and
associated with behavioral impairments.
CELLULAR BRAIN BARRIERS: FIRST LINE
OF DEFENCE
The BBB is known to be established and functional during
embryogenesis in both humans and rodents, specifically
embryonic day 15.5 for mice (Ben-Zvi et al., 2014). The tight
junctions in cerebral vessels and choroid plexus are formed early
in embryonic development, however, the capillaries within the
rodent cortex only begin to appear adult-like during postnatal
days 14–21 (Semple et al., 2013). This is because the main period
of astrocytic differentiation and the increasing coverage of
capillaries with astrocytic end-feet occurs in rodents in the first
3-weeks of life (Caley and Maxwell, 1970; Saunders et al., 2014).
This explains the significant brain iron overload (and associated
behavioral impairments) following neonatal administration of
iron in rodents. Thus, a compromised BBB may play a putative
role in aging and neurodegenerative diseases. For instance,
cerebral vasculature inflammation is regarded as an early event
in the progression of neuroinflammation and Aß pathology
(Biron et al., 2011). BBB inflammation has been observed with
alterations in permeability and upregulation of MECA-32 and
selectin in rodent models of neurodegeneration (Yu et al.,
2012). The activation of the endothelium has been shown to
coincide with increased BBB permeability which may enable
systemic inflammatory cells including monocytes/macrophages
to enter the brain to initiate iron deposition. Systemic
inflammation can induce BBB perturbations leading to increased
microglial/astrocytic activation, iron deposition, protein
aggregation and neurodegeneration (Hernandez-Romero et al.,
2012; Urrutia et al., 2013; Andersen et al., 2014).
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
Brain iron is tightly regulated by a multitude of proteins
and cellular barriers, with perturbation in their metabolism
underlying the observed iron dyshomeostasis during brain aging,
putatively promoting oxidative cellular damage. Neuroimaging,
particularly involving the use of MRI, offers a non-invasive
quantitative approach to study brain aging. However, MRI
is limited by the inability to measure concentrations and
cellular/subcellular location of individual iron species. A multi-
modal approach needs to be adopted, e.g., where MRI
is used together with histological/molecular biology tools.
The latter ascertaining the cellular localization (i.e., neurons,
microglia, or astrocytes) of iron, and how expression of iron-
regulatory proteins changes in healthy and pathological aging (or
neurodegenerative disease) in respective compartments.
Iron dyshomeostasis is increasingly considered a hallmark
of neurodegenerative diseases, where it is associated with
neuroinflammation, protein aggregation, neurodegeneration,
and neurobehavioural deficits (Ward et al., 2014). The exact
mechanistic processes involved in normal and pathological aging
in specific brain areas require further elucidation. To interpret
the regional perturbations in iron and iron-related proteins,
accurate iron mapping using multi-disciplinary approach in
healthy aging and neurodegenerative disorders at different ages
is required. Age and sex are important co-factors that need
to be considered for dissecting pathology aging from healthy
aging. Total subcortical iron levels were found to be lower
in healthy women than men (Persson et al., 2015). Similarly,
worse verbal-memory performance was associated with higher
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hippocampal iron in men but not women (Bartzokis et al.,
2011). It is established that women have lower peripheral iron
levels compared to men, consequently women have reduced
brain iron levels (Whitfield et al., 2003). There is evidence to
suggest that males who have a higher concentration of brain
ferritin iron levels experience an earlier age of onset for acquiring
neurodegenerative diseases including AD and PD (Bartzokis
et al., 2004). Future studies should stratify subjects based on
sex and genetic status to provide greater mechanistic insights in
normal and pathological aging.
The recent deferiprone clinical trials in PD (Devos et al., 2014)
and amyotrophic lateral sclerosis (Martin-Bastida et al., 2017;
Moreau et al., 2017) were well tolerated and showed reductions
in brain iron load, and was associated with improved clinical
performance, and a better quality of life. However, there is
increased incidence of agranulocytosis with deferiprone (Tricta
et al., 2016) and there is a need to develop second generation
of iron chelators without this side-effect (Xie et al., 2016). Based
on the evidence discussed, we suggest a synergistic use of iron-
chelation therapies (Hider et al., 2008) and/or anti-inflammatory
treatments as putative anti-brain aging therapies to counteract
pathological aging observed in neurodegenerative diseases.
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